Plus Therapeutics (PSTV) announced positive data from a retrospective analysis of the CNSide Cerebrospinal Fluid, CSF, Assay Platform at the 2025 Society for Neuro-Oncology/American Society of Clinical Oncology, ASCO, CNS Metastases Conference in Baltimore, Maryland. The presentation, titled “The Oncogenic Flip in Patients with Leptomeningeal Metastatic Disease: Longitudinal Detection in Cerebrospinal Fluid Tumor Cells Reveals Implications for Differential Treatment of the LMD Tumor,” was a retrospective, multi-center analysis of 613 CNSide assays ordered by 19 physicians from 5 institutions at 2 health systems for 218 individual patients. Data Demonstrated: CSF tumor cells detected in 67% patients using CNSide; 66 patients underwent 2 or more CSF draws; 24 patients underwent 5 or more; 20% of patients were found to have a flip in immunocytochemistry detection; and 88% of patients were found to have a flip in FISH probe detection.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSTV:
- Plus Therapeutics Granted Continued Nasdaq Listing
- Plus Therapeutics Approves Key Proposals at Annual Meeting
- Plus Therapeutics files to sell 33M shares of common stock for holders
- Plus Therapeutics’ Innovative Study on Rhenium-186 NanoLiposome for Cancer Metastases
- Plus Therapeutics says CNSide CSF platform will be available for Texas in August